MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...
RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback